Cutler Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $269K | Sell |
1,480
-187
| -11% | -$32.2K | 0.09% | 226 |
|
|
2023
Q4 | $258K | Sell |
1,667
-724
| -30% | -$106K | 0.02% | 633 |
|
|
2023
Q3 | $356K | Sell |
2,391
-1,740
| -42% | -$255K | 0.04% | 529 |
|
|
2023
Q2 | $556K | Sell |
4,131
-1,212
| -23% | -$178K | 0.08% | 294 |
|
|
2023
Q1 | $851K | Sell |
5,343
-9,041
| -63% | -$1.38M | 0.09% | 231 |
|
|
2022
Q4 | $2.32M | Buy |
14,384
+6,584
| +84% | +$1.01M | 0.2% | 107 |
|
|
2022
Q3 | $1.05M | Sell |
7,800
-3,103
| -28% | -$445K | 0.07% | 291 |
|
|
2022
Q2 | $1.67M | Buy |
10,903
+2,173
| +25% | +$332K | 0.12% | 220 |
|
|
2022
Q1 | $1.42M | Sell |
8,730
-20,557
| -70% | -$2.99M | 0.07% | 290 |
|
|
2021
Q4 | $3.96M | Buy |
29,287
+11,706
| +67% | +$1.38M | 0.17% | 117 |
|
|
2021
Q3 | $1.9M | Sell |
17,581
-6,576
| -27% | -$751K | 0.09% | 254 |
|
|
2021
Q2 | $2.72M | Buy |
24,157
+8,078
| +50% | +$910K | 0.13% | 176 |
|
|
2021
Q1 | $1.74M | Sell |
16,079
-18,114
| -53% | -$1.94M | 0.09% | 254 |
|
|
2020
Q4 | $3.66M | Buy |
34,193
+29,979
| +711% | +$2.88M | 0.17% | 119 |
|
|
2020
Q3 | $369K | Sell |
4,214
-5,729
| -58% | -$539K | 0.02% | 639 |
|
|
2020
Q2 | $976K | Sell |
9,943
-3,537
| -26% | -$311K | 0.06% | 296 |
|
|
2020
Q1 | $1.03M | Buy |
13,480
+10,760
| +396% | +$917K | 0.05% | 334 |
|
|
2019
Q4 | $240K | Sell |
2,720
-1,000
| -27% | -$83K | 0.01% | 734 |
|
|
2019
Q3 | $281K | Buy |
3,720
+2,068
| +125% | +$142K | 0.03% | 553 |
|
|
2019
Q2 | $120K | Buy |
1,652
+258
| +19% | +$20.3K | 0.01% | 992 |
|
|
2019
Q1 | $112K | Sell |
1,394
-6,606
| -83% | -$540K | 0.01% | 952 |
|
|
2018
Q4 | $737K | Buy |
8,000
+6,000
| +300% | +$528K | 0.07% | 251 |
|
|
2018
Q3 | $189K | Buy |
2,000
+500
| +33% | +$47.4K | 0.01% | 867 |
|
|
2018
Q2 | $138K | Sell |
1,500
-1,803
| -55% | -$176K | 0.01% | 948 |
|
|
2018
Q1 | $312K | Sell |
3,303
-6,853
| -67% | -$753K | 0.03% | 596 |
|
|
2017
Q4 | $982K | Buy |
10,156
+987
| +11% | +$93K | 0.04% | 338 |
|
|
2017
Q3 | $814K | Buy |
+9,169
| New | +$698K | 0.03% | 426 |
|
|
2017
Q2 | – | Sell |
-1,506
| Closed | -$101K | – | 6258 |
|
|
2017
Q1 | $98K | Sell |
1,506
-5,874
| -80% | -$369K | ﹤0.01% | 1752 |
|
|
2016
Q4 | $462K | Buy |
7,380
+677
| +10% | +$41.3K | 0.02% | 736 |
|
|
2016
Q3 | $422K | Sell |
6,703
-3,946
| -37% | -$255K | 0.02% | 694 |
|
|
2016
Q2 | $659K | Sell |
10,649
-35,751
| -77% | -$2.18M | 0.03% | 448 |
|
|
2016
Q1 | $2.65M | Buy |
46,400
+44,813
| +2,824% | +$2.5M | 0.17% | 76 |
|
|
2015
Q4 | $94K | Buy |
+1,587
| New | +$91.4K | 0.01% | 1829 |
|
Other funds holding ABBV
Cutler Group's ABBV Position: Q1 2024 in Review
Cutler Group reduced its AbbVie (ABBV) stake by 11% in Q1 2024, selling an estimated $32.2K and leaving 1,480 shares worth $269K. The position accounts for 0.09% of the portfolio, ranked #226.
Cutler Group first reported a position in ABBV in Q4 2015 and has held it in 33 quarters since. The position peaked at $3.96M in Q4 2021. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.
- Cutler Group held 1,480 shares of AbbVie worth $269K as of Q1 2024.
- Cutler Group sold 187 AbbVie shares in Q1 2024, an estimated $32.2K.
- AbbVie made up 0.09% of Cutler Group's portfolio in Q1 2024, its #226 holding.
- Cutler Group first reported a position in AbbVie in Q4 2015 and has held it in 33 quarters since.
- Cutler Group's AbbVie position peaked at $3.96M in Q4 2021.
- 3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.